Recently, a study reported that patients with CDH12-enriched bladder cancers have poor outcome of neoadjuvant chemotherapy, and that CDH12-enriched cancer cells exhibit aggressiveness and chemoresistance47. This evidence concerns the gene CDH12 and urinary bladder carcinoma.